Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR

Shencun Fang; Meiling Zhang; Guihong Wei; Kai-Hua Lu

doi:10.18632/oncotarget.23612

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Clinical Research Papers:

Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR

Shencun Fang, Meiling Zhang, Guihong Wei and Kai-Hua Lu _

PDF | HTML | How to cite

Oncotarget. 2018; 9:7175-7181. https://doi.org/10.18632/oncotarget.23612

Metrics: PDF 1238 views | HTML 1932 views | ?

Abstract

Shencun Fang1,3,*, Meiling Zhang2,*, Guihong Wei3 and Kai-Hua Lu2

1Department of Respiratory Medicine Center, Nanjing Chest Hospital, Nanjing, Jiangsu, China

2Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

3Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

*These authors contributed equally to this work

Correspondence to:

Kai-Hua Lu, email: [email protected]

Keywords: non-small-cell lung cancer; angiogenesis; apatinib; VEGFR-2

Received: August 24, 2017 Accepted: November 14, 2017 Published: December 22, 2017

ABSTRACT

Objectives: This study was conducted to evaluate the efficacy and safety of apatinib in advanced NSCLC patients with EGFR wild-type who have failed more than second-line chemotherapy.

Materials and Methods: We retrospectively analyzed patients with EGFR wild-type advanced NSCLC who were treated with apatinib from January 2014 to August 2016. Objective response rate (ORR), disease control rate (DCR), progression free survival (PFS), overall survival (OS), and adverse events (AEs) were reveiwed and evaluated. Univariate and multivariate analyses were performed to determine the prognostic factors.

Results: 36 patients were evaluable for safety and efficacy. 6 patients obtained partial response, and 21 showed stable disease. The ORR and DCR were 16.7% and 75%, respectively. The median PFS and OS were 4.5 months and 8.2 months, respectively. Prognostic variable for a longer OS was good performance status (p = 0.015). Most adverse reactions were mild or moderate.

Conclusions: Apatinib should be recommended as a third- or further- line therapy in advanced NSCLC patients with EGFR wild-type due to its better efficacy and tolerable toxicity.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23612

Publication Alerts

Clinical Research Papers:

Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR

Abstract